Utah-based Intermountain Healthcare and the Icelandic company deCODE Genetics are teaming up on a deep dive into the DNA of half a million patients, a collaboration they hope can reveal connections between the makeup of our genomes and our health.
The partnership, announced Wednesday and dubbed the HerediGene: Population Study, aims to analyze the genomes of 500,000 patients from Intermountain’s network of clinics and hospitals in Utah and Idaho. Scientists and clinical experts from deCODE and Intermountain will compare the genomic data with patients’ medical histories to gain a better understanding of how our genes influence our health.
For deCODE, a subsidiary of Amgen, the project could also point to future therapeutics.
About the Author Reprints
